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ABSTRACT
Objectives Anticitrullinated protein antibody (ACPA)+
individuals with non-speciﬁc musculoskeletal symptoms
are at risk of inﬂammatory arthritis (IA). This study aims
to demonstrate the predictive value of T cell subset
quantiﬁcation for progression towards IA and compare it
with previously identiﬁed clinical predictors of
progression.
Methods 103 ACPA+ individuals without clinical
synovitis were observed 3-monthly for 12 months and
then as clinically indicated. The end point was the
development of IA. Naïve, regulatory T cells (Treg) and
inﬂammation related cells (IRCs) were quantiﬁed by ﬂow
cytometry. Areas under the ROC curve (AUC) were
calculated. Adjusted logistic regressions and Cox
proportional hazards models for time to progression to
IA were constructed.
Results Compared with healthy controls (age adjusted
where appropriate), ACPA+ individuals demonstrated
reduced naïve (22.1% of subjects) and Treg (35.8%)
frequencies and elevated IRC (29.5%). Of the 103
subjects, 48(46.6%) progressed. Individually, T cell
subsets were weakly predictive (AUC between 0.63 and
0.66), although the presence of 2 T cell abnormalities
had high speciﬁcity. Three models were compared:
model-1 used T cell subsets only, model-2 used
previously published clinical parameters, model-3
combined clinical data and T cell data. Model-3
performed the best (AUC 0.79 (95% CI 0.70 to 0.89))
compared with model-1 (0.75 (0.65 to 0.86)) and
particularly with model-2 (0.62 (0.54 to 0.76))
demonstrating the added value of T cell subsets. Time to
progression differed signiﬁcantly between high-risk,
moderate-risk and low-risk groups from model-3
(p=0.001, median 15.4 months, 25.8 months and
63.4 months, respectively).
Conclusions T cell subset dysregulation in ACPA+
individuals predates the onset of IA, predicts the risk and
faster progression to IA, with added value over
previously published clinical predictors of progression.
INTRODUCTION
Over recent years our understanding of the
immune pathways and interactions involved in the
pathogenesis of rheumatoid arthritis (RA) has
evolved substantially. This has had a notable impact
on drug development targeting speciﬁc pathways.
Early RA clinical trials have aided the translation of
ﬁndings and resulted in a vast body of evidence
supporting early diagnosis and immediate treatment
to improve outcomes of patients with RA.1–4
However despite early intervention at RA diagno-
sis, a proportion of individuals fails conventional
therapy and continues with immune dysregulation
and active inﬂammation.5–7 This has led investiga-
tors to focus on identifying disease at its earliest
stage.8 By identifying individuals at a higher risk of
future RA, it is hoped that outcomes can be
improved.
Several groups including our own have reported
on cohorts at high risk to RA.9–15 The most notable
of these are individuals with RA-associated antici-
trullinated protein antibody (ACPA) autoantibodies
and musculoskeletal pain. However, autoantibodies
alone are not sufﬁcient to predict progression to
inﬂammatory arthritis (IA) with only 50% overall
progression over 4 years.14 In recent years there has
been increased interest in the identiﬁcation of bio-
markers that assist the prediction of disease onset in
such cohorts.16–26 The ability to risk stratify indivi-
duals is an attractive option particularly in light of
current strategies concerning personalised medi-
cine. By identifying those at greatest risk, the use of
immunomodulating therapies could be targeted to
prevent progression to disease.
In RA, T cell subset quantiﬁcation provides an
insight into the immune status of the patient.27
Although regulatory T cells (Treg) have been the
focus of many studies including our own, we have
demonstrated that CD4+ T cells are an important
T cell biomarker.7 28–32 Inﬂammation causes the
cells to differentiate into other subsets driven by
proinﬂammatory cytokines such as interleukin (IL)
6 and tumour necrosis factor (TNF) with the
appearance of a novel T cell subset called inﬂamma-
tion related cells (IRCs).29 To date, we have demon-
strated the role of T cell subset analysis in
predicting relapse in DMARD-induced remission,7
the safe discontinuation of TNF blockers31 and,
more recently, methotrexate-induced remission in
early RA.32
We hypothesised that in ACPA+ individuals with
non-speciﬁc symptoms, those with the greatest T
cell subset dysregulation (as determined using naïve
CD4+ T cells, IRC and Treg quantiﬁcation) would
have a greater propensity for progression to arth-
ritis. The aim of this study was to report on the
extent of T cell subset dysregulation in ACPA+
individuals and to determine the potential of T cell
subset analysis as a biomarker of future progression
to clinical arthritis. The confounding effect of clin-
ical parameters previously shown to be predictive
in a clinical model14 was also investigated.
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METHODS
Patients
As previously described,14 individuals with ACPA+ and non-
speciﬁc musculoskeletal symptoms were identiﬁed from regional
primary care services and early arthritis clinics. The primary
care component was adopted by the UK Primary Care Clinical
Research Network (Primary Care Research Network, https://
www.crn.nihr.ac.uk/). Individuals 18 years old or over with a
new musculoskeletal joint symptom presenting to their primary
care physician or health professional were eligible. The follow-
ing exclusion criteria were applied: fulﬁlling the European
League Against Rheumatism (EULAR) 2010 classiﬁcation cri-
teria for RA, history of IA diagnosed by a rheumatologist; pres-
ence at baseline of clinically detected IA conﬁrmed by a
rheumatologist; and use of disease-modifying antirheumatic
drugs (DMARDs). ACPA status was determined using the com-
mercially available anti-CCP2 (ImmunoCAP method; Phadia,
Sweden, Germany). Eligible participants were recruited to
a single centre research clinic as part of a prospective observa-
tion cohort. The clinical end point was the development of IA
on clinical examination. All participants provided informed
consent for the study prior to recruitment. One hundred and
six healthy controls provided informed consent for a blood
sample draw.
Clinical assessments
At baseline, demographic details were collected and participants
completed patient questionnaires, provided a clinical history of
symptoms and had a systems examination by a rheumatologist
including a joint count. Individuals attended 3-monthly visits
for the 1st year and as clinically indicated thereafter for up to
6.5 years. Participants were able to attend in between visits
should they develop any new symptoms. Smoking status was
recorded including number of cigarettes smoked and duration.
HLA-DRB1 shared epitope (SE) status (low-resolution) was con-
sidered positive with the presence of one or two copies of the
following alleles: HLA- DRB1*01, DRB1*04 and DRB1*10 in
the HLA-DRB1 locus.33 34
T cell subset analysis
Peripheral blood was collected into EDTA. Flow cytometry was
performed as previously described.32 Brieﬂy, naïve and IRC
CD4+ T cell subsets were identiﬁed based on their expression
of CD45RB-FITC (clone MEM-55, Serotec, Oxford, UK),
CD45RA-PE (clone F8-11-13, Serotec), and CD62L-APC (clone
145/15 Coulter, High Wycombe, UK). Treg were quantiﬁed by
cell surface staining for CD4-Pacifc blue (clone RPA-T4,
Bechton Dickson (BD), Oxford, UK), CD25-APC (clone 2A3,
BD) and CD127-PE (R34.34, Beckman coulter), followed by
intracellular staining for FOXP3-FITC (clone PCH101
eBioscience, San Diego, California, USA) using the antihuman
Foxp3 staining kit (Insight Biotechnology, Wembley, UK). Flow
cytometry analysis was performed on a LSRII cytometer (BD),
using BD Biosciences FACSDIVA software. Subset frequencies
were reported as percentage of gated CD3+/CD4+ T cells.
Statistical analysis
Reference limits for each T cell subset (lower 95% limit of
normal for naïve and Treg, upper 95% limit of normal for IRC)
were obtained using data from 106 healthy controls (see online
supplementary material). We categorised T cell subset values of
ACPA+ patients as normal or abnormal according to the lower
or upper reference limits, one-sample binomial tests were used
to assess whether the proportion of participants with abnormal
values differed from the expected 5%. Pearson’s χ2 tests were
used to identify associations between SE and T cell subset
abnormalities.
Unadjusted associations between T cell subset frequencies
and progression to IA
Non-parametrical area under the ROC (AUROC) curve was cal-
culated for each subset. Additionally, sensitivity and speciﬁcity
of each subset for predicting progression to IA at any time
during follow-up were calculated, with 95% CIs estimated by
the Wilson method.
Adjusted associations between T cell subset frequencies
and progression to IA
Binary logistic regression models of the occurrence of progres-
sion to IA, and Cox proportional hazards models of time to
progression were constructed to adjust for the following vari-
ables: age; SE status (negative/positive); smoking (never/ever);
ACPA titre. Clinical variables from a previously published model
were also included: physician assessed small joint tenderness
(absent/present) and duration of early morning stiffness (EMS)
(<30 min/≥30 min). Further details on methodology are pro-
vided in online supplementary material. Akaike Information
Criteria (AIC) values were used to compare the different models
(lower AIC indicates a better quality model). The predicted
probability of progression obtained from the ﬁnal logistic regres-
sion model (model-3) was calculated for patients with full data;
patients were then categorised as being at low (<20%), moder-
ate (20–80%) or high (>80%) risk. Kaplan-Meier plots and
log-rank tests were then produced for time to progression, using
these risk groups.
Analyses were performed using STATAV.13.1.
RESULTS
Reference limit
Samples from 106 healthy controls (HC) enabled the develop-
ment of reference range for each T cell subset (see online
supplementary material). Naïve cells frequency was lower in
older HC29 but did not differ by gender (see online
supplementary material ﬁgure S1 and table S1). IRCs were not
related to demographic parameters (see online supplementary
ﬁgure S2). A clear positive association between Treg frequency
and age (see online supplementary ﬁgure S3 and table S3) and
no difference by gender is reported here as recently described.35
Progression to inﬂammatory arthritis
Of the participants 48/103 (46.6%) developed synovitis during
follow-up, with the majority of individuals, 30/48 (62.5%)
progressing within 12 months. Baseline clinical and demo-
graphic characteristics are presented in table 1.
T cell subset and progression
No abnormal lymphocyte counts were observed in these partici-
pants and their CD4+T cells were not different between pro-
gressors and non-progressors (data not shown, p=0.794).
Frequencies observed for all three subsets are presented in
ﬁgure 1.
The values observed in ACPA+ individuals were then dichot-
omised as within or below normal range (deﬁned by the lower
limit of normal (LLN) as indicated with the line on ﬁgure 1),
for naïve T cell and Treg and within or above normal range for
IRC (deﬁned by the upper limit of normal (ULN)). In subjects
with full T cell data available for all three subsets (n=95/103), a
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signiﬁcantly larger proportion of ACPA+ participants had
abnormal values (table 2, p<0.001 for all three subsets). A third
of ACPA+ individuals had no T cell abnormalities (37.9%), over
a third (40.0%) had either one of the three abnormalities and
the remaining subjects had two (18.9%) or three (3.2%)
abnormalities.
We observed these patients for up to 5 years before progres-
sion to synovitis and obtained a repeat blood sample at an
annual visit for 55 of them. Of 26 progressors, 18 participants
changed dichotomisation group from normal to below-LLN for
naïve or Treg or increase in IRC to above-ULN. Of the 29 non-
progressors, only 3 showed changes in dichotomisation.
Using categorised subset values, AUROC analysis conﬁrmed
that T cell subsets were predictive individually (table 2).
AUROC comprised between 0.63 and 0.66 (p<0.03) with the
best individual predictor being Treg, then naïve cells and last
IRCs (table 2). Individually, naïve, IRC and Treg subsets also
demonstrated high speciﬁcities (table 2, 71.7–83.0%) for predic-
tion of progression to IA but had relatively low sensitivities
(28.6–45.2%). Consistent with the area under the curve (AUC)
analysis, CIs for the unadjusted ORs for all three subsets indi-
cated that, with no adjustment other than age in the case of
naïve cells and Treg, each subset was associated with progression
to IA (table 2). Higher naïve cell and Treg frequencies were
protective, as would be expected, while higher IRC frequencies
were associated with increased odds of progression.
T cell model of progression to IA
Our results suggest associations between T cell subsets and pro-
gression; however they could have been confounded by genetic
and environmental factors such as SE and smoking.36–38
Furthermore, clinical parameters routinely collected in ACPA+
individual were previously used to build a prediction model14
and it was important to assess the added value to T cell subset
quantiﬁcation over this initial clinical model. We used regression
and compared the performance of three models: a T cell only
model (model-1), a clinical only model (model-2) and a com-
bined model (model-3). Details are provided in online
supplementary material table S3.
AUROC curves were constructed for all three models
(ﬁgure 2). Although the AUROC curve for the combined model
(model-3 AUC 0.79) was better than for the T cell only model
(model-1 AUC 0.75), the AIC values suggested that the
Figure 1 Graphical representation of the T cell abnormalities. T cell subsets were quantiﬁed and data presented in relation to the age of the
participants. Dotted lines represent the lower limit of normal (LLN) for naive cells and regulatory T cells (Treg) and the upper limit of normal (ULN)
for inﬂammation related cells (IRC).
Table 1 Clinical characteristics of ACPA+ individuals (n=103)
Characteristic Result
Progressed (ever): % (n) 46.6% (48)
Duration of follow-up (months) median (range) 18.4 (0.1 to 79.6)
Age (years) mean (SD; range) 52.6 (11.7; 27 to 79)
Female: % (n) 71.8% (74)
SE positive %(n)* 73.5% (72)
High positive ACPA and/or RF†: % (n) 85.4% (88)
Smoker: % (n)
Non-smoker 30.1 (31)
Ex-smoker 41.7 (43)
Current smoker 28.2 (29)
EMS≥30 mins: % (n) 34.0% (35)
Small joint symptoms: % (n) 43.7% (45)
*Available in 98/103 patients.
†Determined as >3×upper limit of normal.
ACPA, anticitrullinated protein antibody; EMS, early morning stiffness; RF, rheumatoid
factor; SE, shared epitope.
Table 2 Unadjusted T cell analysis of progression to IA
Reduced naïve
cell frequency
Elevated IRC
frequency
Reduced Treg
frequency
Observed proportion of
patients (observed/n)
22.5% 30.3% 35.4%
23/102 30/99 35/99
Calculated proportion* 22.1% 29.5% 35.8%
95% CI 14.2% to 31.8 20.6% to 39.7 26.2% to 46.3
Standardised binomial test z 7.4 10.7 13.5
p Value <0.001 <0.001 <0.001
AUROC* 0.63 0.63 0.66
95% CI 0.52 to 0.74 0.52 to 0.74 0.55 to 0.77
p Value 0.029 0.032 0.008
Sensitivity* 28.6 % 35.7 % 45.2 %
95% CI 17.2 to 43.6 23.0 to 50.8 31.2 to 60.1
Specificity* 83 % 75.5 % 71.7 %
95% CI 70.8 to 90.8 62.4 to 85.1 58.4 to 82.0
Naïve
(per %)†
IRC
(per %)
Treg
(per %)†
Unadjusted OR* 0.94 1.15 0.70
95% CI 0.90 to 0.98 1.00 to 1.32 0.56 to 0.89
*In patients with data for all three T cell subsets n=95.
†Adjusted for age.AUROC, area under the ROC curve; IA, inflammatory arthritis; IRC,
inflammation related cell; Treg, regulatory T cells.
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combined model-3 did not represent a major improvement over
the T cell only model-1 (see online supplementary table S3,
116.3 vs 115.7), but it did offer added predictive value over the
clinical model-2 (AIC 116.3 vs 125.0). Both of these adjusted
models improved on the values achieved by looking at each
subset individually (table 2, AUCs comprised between 0.63 and
0.662).
Applying model-3, we then stratiﬁed patients into three
groups according to their predicted risk of progression: low (0–
19%, n=20), moderate (20–79%, n=56) or high (80–100%,
n=12) to examine its potential clinical utility. The majority of
individuals in the high-risk group progressed (64%, 9/12)
compared with those in the low-risk (5%, 1/20) and
moderate-risk (57%) groups.
Time to progression to IA
Using the three logistic regression models, Cox regression was
constructed to investigate time to progression as it has more
relevance clinically (see online supplementary table S4). The
trends identiﬁed were similar. All three T cell subsets showed
signs of association with the odds of progression in model-1
and model-3 (see online supplementary table S4, HR), however,
IRCs were the most signiﬁcant in this analysis. Using Harrell’s C
as an indication of performance of the Cox regression, the com-
bined model-3 allowed 69% of randomly chosen pairs of pro-
gression times to be correctly ordered compared with 65% for
the T cell only model-1 and 60% in the clinical only model-2
(see online supplementary table S4).
Figure 3 presents Kaplan-Meier plots for time to progression
according to the predicted risk categories from logistic regres-
sion for the three models. Time to progression differed signiﬁ-
cantly according to risk groups in model-1 (χ2=6.04, p=0.049)
and model-3 (χ2=13.43, p=0.001), although there seemed to
be little difference between the curves for patients at moderate
risk or high risk of progression. For model-2, none of the
patients at low risk progressed so we could not compute time to
progression for that group. The median time to progression in
the moderate-risk group was 34.1 months with an overall sig-
niﬁcant difference between the groups (χ2=4.60, p=0.032). In
model-3, those within the high-risk group progressed to IA
much more rapidly (median 15.4 months, (95% CI 14.3 to
40.8)) compared with those in the moderate-risk group
(35.1 months (25.8–44.4)) and the low-risk group (63.4 months
(57.9–69.3)).
DISCUSSION
This is the ﬁrst analysis exploring T cell subset quantiﬁcation
within a prospectively followed ‘at-risk’ population. We demon-
strated that T cell subsets dysregulation predates the onset of IA
in ACPA+ individuals. Compared with healthy controls,
two-thirds of the ACPA+ participants demonstrated T cell
abnormalities in one or more of the three subsets analysed,
these subsets being individually predictive (table 2).
Furthermore, the potential use of these biomarkers within an
Figure 2 ROC graphical representation of the three logistic regression
models. Binary logistic regression models of the occurrence of
progression to inﬂammatory arthritis (IA) using model-1 T cell subset
only (orange line), model-2 clinical parameters (red line) and the
combined Model-3 (green line) were constructed. The area under the
ROC for the predicted probability of progression from model-1 was 0.75
(95% CI 0.65 to 0.85), which represents an improvement over model-2
(0.62 (0.54 to 0.76)). Model-3 showed the best results with an area
under the ROC at 0.79 (0.79 to 0.89).
Figure 3 Kaplan-Meier graph of cumulative inﬂammatory arthritis (IA)-free survival according to predicted probability of progression in the three
models. Anticitrullinated protein antibody (ACPA)+ subjects were stratiﬁed into three groups according to their predicted risk of progression: low
(green line, 0–19%), moderate (orange line, 20–79%), high (red line, 80-100%) calculated for all three models. Kaplan-Meier plots for time to
progression were built according to the predicted risk categories from logistic regression model-1 and model-3. Time to progression differed
signiﬁcantly according to risk of progression, in model-1 (χ2=6.04, p=0.049) and model-3 (χ2=13.43, p=0.001), although there was little difference
between the curves for patients in the moderate-risk or high-risk groups in both models. For model-2, the median time to progression in the
moderate-risk group is 34.1 months with an overall signiﬁcant difference between the two risk groups (χ2=4.60, p=0.032).
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exploratory prediction model is presented. Adjusted analysis
demonstrated the added value of combining T cell subsets and
clinical data (ﬁgure 2 and see online supplementary table S3)
and the time to progression was signiﬁcantly reduced with
increasing risk of progression (ﬁgure 3, see online supplemen-
tary table S4).
Individuals with systemic autoimmunity and musculoskeletal
(MSK) symptoms (+/−arthralgia) but no clinical synovitis
(groups c+d using EULAR terminology8) have been studied pro-
spectively in several research centres.10 14 Although the suggested
terminology has assisted in classifying individuals there remains
great heterogeneity considering the possible genetic predispos-
ition, environmental factors, symptomology, and ultimately pro-
gression or not towards arthritis reported in these studies. This
limits the transferability of ﬁndings between studied populations,
however, the information gained offers a unique opportunity to
understand possible ‘at-risk’ states and triggers. Although 53.4%
(55/103) of our subjects have yet to develop IA, some progressed
rapidly—these individuals should beneﬁt from early targeted
therapies. Identifying these individuals is therefore a clinical pri-
ority. One group of interest would be those with two T cell
abnormalities and a high speciﬁcity (but low sensitivity) for pro-
gression. However it may be equally important to be able to
identify and reassure those who are at little risk.
The positive and negative predictive values of the combined
model-3 were 60% (41/68) and 95% (19/20), respectively.
While a positive predictive value (PPV) of 60% is lower than
clinically desired, it is an improvement on the T cell model-1
and clinical model-2 (54% and 50%, respectively). Furthermore
the negative predictive value (NPV) of 95% of the combined
model-3 suggests that it is possible to predict quite accurately
which participants are unlikely to progress and who may there-
fore be safely discharged. Compared with the clinical model-2
which is best at predicting non-progression (NPV 100%) this
suggests that adding T cell data to clinical data clearly improved
the ability to determine progressors. Reviewing data from
annual visits further strengthened the concept of T cell abnor-
malities developing over time, and given that progression may
happen up to 5 years later it may not be that unexpected that
PPV is 60% at baseline. This supports the need for annual
review in the moderate-risk (and high-risk) group with
re-evaluation of the risk score and tailoring of clinical care.
Several other biomarkers of progression have been considered
including imaging modalities, possible pathogens and several
immune-mediated markers.16 19 25 26 39–41 Although a speciﬁc
cytokine proﬁle could not be associated with progression,41 the
hypothesis of a mounting immune response prior to IA develop-
ment has been supported by reports of a broadening of the rep-
ertoire of citrullinated peptides associated with imminent
progression to IA19 as well as a possible IFN-type-1 gene expres-
sion signature.26 There are limited studies investigating T cell
subsets within an ‘at-risk’ population. We have demonstrated
that all three subsets are individually associated with progres-
sion. Although all three subsets are part of the CD4+ T cell
pool, they are generated through different mechanisms and
their individual frequencies are not related to one another. The
development of IRCs is the result of inﬂammatory processes
whereas naïve cells are generated in the thymus and released to
circulate in the blood. Naturally occurring Treg also develop in
the thymus, however, their frequency in the blood is not directly
related to thymic release.42 Therefore the individual status of all
three subsets reﬂects the immunological state of an individual at
a particular point in time (ie, a biomarker). A small cross-
sectional study of 26 seropositive patients with arthralgia
reported on peripheral naïve T cells (CD3+CD4+CD45RO
−CCR7+),43 however, no difference between health, RA and
arthralgia was reported in this study. Naïve CD4+ T cells are
conventionally identiﬁed using markers such as CD45RA+,
CD62L+ and CD44+, but less often using an exclusion marker
(CD45RO−) and an activation marker (CD197/CCR7). It is
therefore difﬁcult to compare these data with our ﬁndings; also,
given the use of a mixed cohort of ACPA+ and/or IgM-FR+
patients with arthralgia, several studies having showed clear
reduction of naïve cells and Treg in early RA.28 30–32 Loss of
immune regulation may be an important immunological event
in the progression of a disease. However, at this stage, we
cannot establish that one of the abnormalities is ‘more import-
ant’ than another. Our data suggest that all three are contribut-
ing to the risk, as the modelling demonstrates independent
predictive value, each possibly reﬂecting a different aspect of RA
pathogenesis.
To date, ﬂow cytometry in patients with RA has been predom-
inately performed in a research setting, however we have estab-
lished a pathway within our local National Health Service
(NHS) services to make the test routinely available and the data
presented were mostly generated using this facility. It is hoped
that this approach will offer robust sample processing and cap-
acity to allow for validation of these results. To be of signiﬁcant
clinical utility, it will be necessary to identify patients at high
risk of progression over a known (and ideally short) period of
time. Replication of the current ﬁndings will enable this to
occur.
Our current model produces a risk prediction per % of naïve
cell, Treg or IRC lost or gained, therefore relating the strength
of the prediction to the levels of numerical T cell abnormalities.
However, deﬁning a threshold level of abnormality would be
more practical for a risk score. The current and previously pub-
lished clinical models14 were pilot analyses providing prelimin-
ary biomarkers. In this study, clinical predictors performed
either as well (strong positive ACPA), worse (EMS) or better
(small joint involvement) than previously, with the overall result
that the clinical model-2 is performing slightly less well. This is
not unexpected as predictive models are known to suffer from
coefﬁcient shrinkage.44 Nevertheless, the added value of com-
bining T cell data with clinical parameters is clearly demon-
strated. Our plan is to ﬁnalise the combined models in a larger
group of participants, developing rules for clinical application
and including a threshold for T cell abnormalities.
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